Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 6/20 | 0.64 |
| ▸ | LMNA | P02545 | 3/20 | 0.64 |
| ▸ | THRB | P10828 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.38 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.38 |
| ▸ | SLC22A1 | O15245 | 3/20 | 0.35 |
| ▸ | SLC22A2 | O15244 | 1/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.35 |
| ▸ | DNM1 | Q05193 | 4/20 | 0.33 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Pentane SCHEMBL1825700 | 0.96 | TSHR (0.58) | TSHRLMNATHRBALDH1A1TDP1 | |
| Pentane SCHEMBL3094656 | 0.96 | TSHR (0.58) | TSHRLMNATHRBALDH1A1TDP1 | |
| Hexane SCHEMBL29124909 | 0.91 | TSHR (0.58) | TSHRLMNATHRBALDH1A1SLC22A1 | |
| Hexane SCHEMBL27826796 | 0.91 | TSHR (0.58) | TSHRLMNATHRBALDH1A1SLC22A1 | |
| Heptane SCHEMBL28681950 | 0.87 | TSHR (0.67) | TSHRLMNATHRBALDH1A1SLC22A1 | |
| Undecane SCHEMBL28453375 | 0.87 | TSHR (0.67) | TSHRLMNATHRBALDH1A1SLC22A1 | |
| Undecane SCHEMBL27865572 | 0.87 | TSHR (0.67) | TSHRLMNATHRBALDH1A1SLC22A1 | |
| Octane SCHEMBL27624 | 0.87 | TSHR (0.67) | TSHRLMNATHRBALDH1A1SLC22A1 | |
| Octane SCHEMBL27625 | 0.87 | TSHR (0.67) | TSHRLMNATHRBALDH1A1SLC22A1 | |
| Heptane SCHEMBL28458543 | 0.87 | TSHR (0.67) | TSHRLMNATHRBALDH1A1SLC22A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 165 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-111163809-B | Transglutaminase conjugation method and linker | 保罗·谢勒学院 | 2024-07-02 | — | — | CN | claimed |
| CN-118159298-A | Method for producing antibody-linker conjugates | 阿拉里斯生物技术股份公司 | 2024-06-07 | — | — | CN | claimed |
| WO-2024086246-A2 | 2-SUBSTITUTED 3,4 A, 5, 7, 8, 8 A-HEXAHYDRO-4H-THIOP YRANO [4,3- DJPYRIMIDIN-4-ONES FOR WOUND TREATMENT | Eluciderm Inc. (US) | 2024-04-25 | — | — | WO | claimed |
| CN-116801910-A | Means and methods for producing antibody-linker conjugates | 阿拉里斯生物技术股份公司 | 2023-09-22 | — | — | CN | claimed |
| CN-116406302-A | Method of transglutaminase conjugation with amino acid based linkers | 阿拉里斯生物技术股份公司 | 2023-07-07 | — | — | CN | claimed |
| CN-113613679-A | Transglutaminase conjugation methods for glycine-based linkers | 保罗·谢勒学院 | 2021-11-05 | — | — | CN | claimed |
| CN-111163809-A | Transglutaminase conjugation methods and linkers | 保罗·谢勒学院 | 2020-05-15 | — | — | CN | claimed |
| EP-3632920-A1 | METHODS FOR PREPARING BRIDGED BI-AROMATIC LIGANDS | Univation Technologies, LLC (US) | 2020-04-08 | — | — | EP | claimed |
| EP-3285923-B1 | BRIDGED BI-AROMATIC LIGANDS AND OLEFIN POLYMERIZATION CATALYSTS PREPARED THEREFROM | UNIVATION TECH LLC (US) | 2019-07-17 | — | — | EP | claimed |
| US-10195589-B2 | Bridged bi-aromatic ligands and olefin polymerization catalysts prepared therefrom | UNIVATION TECHNOLOGIES, LLC (US) | 2019-02-05 | — | — | US | claimed |
| CN-109232204-A | A kind of synthetic method without transition metal-catalyzed diarylethene | 绍兴文理学院 | 2019-01-18 | — | — | CN | claimed |
| US-20180147562-A1 | BRIDGED BI-AROMATIC LIGANDS AND OLEFIN POLYMERIZATION CATALYSTS PREPARED THEREFROM | UNIVATION TECHNOLOGIES, LLC (US) | 2018-05-31 | — | — | US | claimed |
| EP-3285923-A1 | BRIDGED BI-AROMATIC LIGANDS AND OLEFIN POLYMERIZATION CATALYSTS PREPARED THEREFROM | Univation Technologies, LLC (US) | 2018-02-28 | — | — | EP | claimed |
| WO-2016172097-A1 | BRIDGED BI-AROMATIC LIGANDS AND OLEFIN POLYMERIZATION CATALYSTS PREPARED THEREFROM | UNIVATION TECHNOLOGIES, LLC (US) | 2016-10-27 | — | — | WO | claimed |
| CN-111163809-B | Transglutaminase conjugation method and linker | 保罗·谢勒学院 | 2024-07-02 | — | — | CN | disclosed |
| CN-118159298-A | Method for producing antibody-linker conjugates | 阿拉里斯生物技术股份公司 | 2024-06-07 | — | — | CN | disclosed |
| WO-2024086246-A2 | 2-SUBSTITUTED 3,4 A, 5, 7, 8, 8 A-HEXAHYDRO-4H-THIOP YRANO [4,3- DJPYRIMIDIN-4-ONES FOR WOUND TREATMENT | Eluciderm Inc. (US) | 2024-04-25 | — | — | WO | disclosed |
| WO-2008119162-A1 | METHODS OF PREPARING PRIMARY, SECONDARY AND TERTIARY CARBINAMINE COMPOUNDS IN THE PRESENCE OF AMMONIA | KANATA CHEMICAL TECHNOLOGIES INC. (CA) | 2008-10-09 | — | — | WO | disclosed |
| WO-2008021029-A2 | PROCESS FOR MAKING LACTAM TACHYKININ RECEPTOR ANTAGONISTS | MERCK & CO., INC. (US) | 2008-02-21 | — | — | WO | disclosed |
| WO-2008021926-A2 | MODULATORS OF GLUCOCORTICOID RECEPTOR, AND/OR AP-1, AND/OR NF-KB ACTIVITY AND USE THEREOF | BRISTOL-MYERS SQUIBB COMPANY (US) | 2008-02-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10195589-B2 | Bridged bi-aromatic ligands and olefin polymerization catalysts prepared therefrom | WASF2, WEE2, PICALM | TSHR 4569/4885LMNA 4204/4885THRB 4552/4885 |
| US-20180147562-A1 | BRIDGED BI-AROMATIC LIGANDS AND OLEFIN POLYMERIZATION CATALYSTS PREPARED THEREFROM | WASF2, WEE2, PICALM | TSHR 4569/4885LMNA 4204/4885THRB 4552/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.